Boehringer acquires Korean approval of IPF treatment ‘Ofev’
Boehringer Ingelheim Korea(CEO Ki-Hwan Park) announced acquisition of product approval for its idiopathic pulmonary fibrosis(IPF) treatment, Ofev Soft Cap(generic name: nintedanib esylate), from the Korean Ministry of Food and Drug Safety(MFDS) on the 21st.
Ofev Soft Cap has two volume types, 1...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
